Background
SH35/SH80 evolved from an effort to improve upon the anti-tumor activity of XK469. XK469 is a compound, currently in Phase 1 clinical trials. The clinical trials include patients with bladder, breast, colorectal, esophageal, head and neck, kidney, liver, lung, mesothelioma, pancreas and sarcoma cancers. Moving a chlorine atom from one position to another destroys the anti-tumor activity and makes the compound an herbicide. The inventors substituted several different atoms in a specified region of XK469 to determine if anti-tumor activity was enhanced or decreased.
Technology
By introducing a bromo compound to the designated site on XK469, (SH80) the inventors demonstrated greater anti-tumor activity as compared to one having a chloro (SH53) or fluoro compound added. All 3 demonstrated anti-tumor activity and activity greater than the original compound XK469.
Competitive Advantages
- Compounds are more effective than the currently tested XK469
- Lower amount is required in order to see effect
- Possible lower side effects experienced
- SH80 is more stable
-Allows for longer-active dosing
Patent Status
Application Pending